Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06814912Not ApplicableCompleted

Evaluation of Virtual Reality Headsets on Cancer Patients During Day Hospital Stay

Role: lead

NCT06807034Phase 4Active Not Recruiting

Impact of the Oral Microbiota on Relapse in HNSCC Patients

Role: lead

NCT06536127Not ApplicableRecruiting

Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer

Role: lead

NCT01143285Not ApplicableCompleted

Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer

Role: collaborator

All 4 trials loaded